ANNEX 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND     
EFFECTIVE USE OF THE MEDICINAL PRODUCT   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The MAH shall agree the details of a controlled distribution system with the National Competent 
Authorities and must implement such programme nationally to ensure that prior to prescribing all 
health care professionals who intend to prescribe and/or dispense Tracleer are provided with a 
Prescriber Kit containing the following: 
• 
Information about Tracleer 
• 
Patient Information Booklet/Patient Reminder Card 
The Member States shall ensure that the MAH shall set up a surveillance programme/registry to 
collect information on the demographics, safety and outcome data from patients prescribed 
Tracleer to reduce the number of new digital ulcers in patients with systemic sclerosis and 
ongoing digital ulcer disease. The data to be collected shall be agreed with the CHMP.  Details of 
the operation of the surveillance programme/registry shall be agreed with the National Competent 
Authorities in each Member State. 
The patient information booklet for patients prescribed Tracleer should include the following key 
elements: 
• 
• 
• 
• 
• 
• 
• 
That Tracleer is teratogenic in animals 
That pregnant women must not take Tracleer 
That women of child bearing potential must use effective contraception 
That hormonal contraceptives on their own are not effective 
The need for regular pregnancy tests 
That Tracleer causes a decrease in haemoglobin and the need for regular blood tests 
That Tracleer is hepatotoxic and the need for regular monitoring of liver function 
The MAH shall agree with each National Competent Authority the content of a "Reminder 
Letter" to all known prescribers of Tracleer, reminding them of the safety concerns with Tracleer 
in relation to pregnancy. 
 
 
 
 
